Table 3.
Pharmacokinetic parameters of multiple‐dose RN317 s.c. 300 mg dosing (Q28d) in subjects with hypercholesterolemia receiving ongoing statin therapy
| RN317 300 mg s.c. dose at day 57 | |
|---|---|
| (n = 13) | |
| n * | 13 |
| Cmax, μg/ml | 16.06 (38) |
| Tmax, h | 72.2 (70.3–169) |
| N* | 13 |
| AUCtau, μg.h/ml/mg | 7,692 (37) |
| Rac | 1.226 (16) |
| t1/2, days | 18.77 ± 3.82 |
Data shown are geometric mean (%CV) for all parameters except for Tmax where median (min, max) is shown, and t1/2 where arithmetic mean ± SD is shown.
*n is the number of subjects in the treatment group and contributing to the mean; N is the number of subjects with a well‐characterized terminal phase. AUCtau, area under the plasma concentration–time curve during a dosage interval (tau); Cmax, maximum concentration; Rac, observed accumulation ratio based on AUC; SD, standard deviation; t1/2, terminal half‐life; Tmax, time to reach maximum concentration.